Jeffrey M Leiden is Executive Chairman of VERTEX PHARMACEUTICALS INC . Currently has a direct ownership of 9,994 shares of VRTX, which is worth approximately $4.51 Million. The most recent transaction as insider was on Aug 30, 2024, when has been sold 3,784 shares (Common Stock) at a price of $499.0 per share, resulting in proceeds of $1,888,216. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 9.99K
27.46% 3M change
55.43% 12M change
Total Value Held $4.51 Million

JEFFREY M LEIDEN Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 30 2024
SELL
Open market or private sale
$1,888,216 $499.0 p/Share
3,784 Reduced 27.46%
9,994 Common Stock
Feb 20 2024
SELL
Payment of exercise price or tax liability
$1,731,948 $420.58 p/Share
4,118 Reduced 23.01%
13,778 Common Stock
Feb 15 2024
SELL
Open market or private sale
$1,951,189 $419.16 p/Share
4,655 Reduced 20.64%
17,896 Common Stock
Feb 14 2024
SELL
Open market or private sale
$1,825,338 $419.04 p/Share
4,356 Reduced 16.19%
22,551 Common Stock
Feb 13 2024
SELL
Open market or private sale
$308,898 $419.13 p/Share
737 Reduced 2.67%
26,907 Common Stock
Feb 12 2024
SELL
Open market or private sale
$1,115,015 $419.81 p/Share
2,656 Reduced 8.77%
27,644 Common Stock
Feb 09 2024
SELL
Payment of exercise price or tax liability
$3,402,211 $422.74 p/Share
8,048 Reduced 20.99%
30,300 Common Stock
Feb 08 2024
SELL
Payment of exercise price or tax liability
$1,137,827 $421.73 p/Share
2,698 Reduced 6.57%
38,348 Common Stock
Feb 07 2024
BUY
Grant, award, or other acquisition
-
7,707 Added 15.81%
41,046 Common Stock
Feb 06 2024
BUY
Grant, award, or other acquisition
-
30,916 Added 48.11%
33,339 Common Stock
Jan 08 2024
SELL
Open market or private sale
$2,785,977 $419.07 p/Share
6,648 Reduced 73.29%
2,423 Common Stock
Dec 13 2023
SELL
Open market or private sale
$5,338,929 $399.8 p/Share
13,354 Reduced 59.55%
9,071 Common Stock
Oct 16 2023
SELL
Open market or private sale
$4,847,788 $374.0 p/Share
12,962 Reduced 36.63%
22,425 Common Stock
May 08 2023
SELL
Open market or private sale
$392,625 $349.0 p/Share
1,125 Reduced 3.08%
35,387 Common Stock
May 05 2023
SELL
Open market or private sale
$307,509 $349.84 p/Share
879 Reduced 2.35%
36,512 Common Stock
May 03 2023
SELL
Open market or private sale
$1,579,828 $350.45 p/Share
4,508 Reduced 10.76%
37,391 Common Stock
May 02 2023
SELL
Open market or private sale
$2,264,272 $351.05 p/Share
6,450 Reduced 13.34%
41,899 Common Stock
Feb 24 2023
SELL
Payment of exercise price or tax liability
$3,969,617 $289.12 p/Share
13,730 Reduced 22.12%
48,349 Common Stock
Feb 13 2023
SELL
Payment of exercise price or tax liability
$3,979,981 $298.26 p/Share
13,344 Reduced 17.69%
62,079 Common Stock
Feb 02 2023
SELL
Payment of exercise price or tax liability
$1,137,195 $317.83 p/Share
3,578 Reduced 4.53%
75,423 Common Stock
Feb 01 2023
BUY
Grant, award, or other acquisition
-
76,578 Added 49.22%
79,001 Common Stock
Jul 25 2022
SELL
Open market or private sale
$37,165,712 $281.39 p/Share
132,079 Reduced 98.2%
2,423 Common Stock
Jul 25 2022
BUY
Exercise of conversion of derivative security
$5,494,139 $91.05 p/Share
60,342 Added 30.97%
134,502 Common Stock
Apr 13 2022
SELL
Open market or private sale
$4,563,653 $289.04 p/Share
15,789 Reduced 17.55%
74,160 Common Stock
Feb 24 2022
SELL
Payment of exercise price or tax liability
$2,766,448 $227.86 p/Share
12,141 Reduced 11.89%
89,949 Common Stock
JML

Jeffrey M Leiden

Executive Chairman
Boston, MA

Track Institutional and Insider Activities on VRTX

Follow VERTEX PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VRTX shares.

Notify only if

Insider Trading

Get notified when an Vertex Pharmaceuticals Inc insider buys or sells VRTX shares.

Notify only if

News

Receive news related to VERTEX PHARMACEUTICALS INC

Track Activities on VRTX